Elsevier

Clinical Therapeutics

Volume 29, Issue 9, September 2007, Pages 1915-1923
Clinical Therapeutics

A 6-Week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%

https://doi.org/10.1016/j.clinthera.2007.09.006Get rights and content

Abstract

Objective: The aim of this study was to compare the tolerability and efficacy of once-daily travoprost 0.004% versus latanoprost 0.005% for 6 weeks followed by 6 weeks of once-daily travoprost 0.004% in decreasing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH).

Methods: This multicenter, randomized, doublemasked, active-controlled, parallel-group trial was conducted at 32 centers across Latin America. Patients aged ≥18 years with OAG or OH were randomly assigned to receive topical travoprost 0.004% or latanoprost 0.005% 1 drop QD (9 PM) for 6 weeks (masked phase). At 6 weeks, all patients were assigned to receive open-label travoprost 0.004% 1 drop QD (9 PM) for 6 additional weeks (open-label phase). Study visits were scheduled at weeks 1, 2, 4, 6, 8, and 12. At each study visit, IOP was measured at 5 PM (±1 hour; ~20 hours after study drug administration). IOP changes from baseline were combined (pooled) from the 1-, 2-, 4-, and 6-week data to provide a comparison between the 2 treatment groups. Ocular adverse events (AEs) were monitored using slit-lamp examination.

Results: A total of 302 patients were enrolled (travoprost group, 155 patients; latanoprost group, 147 patients). The mean (SD) age of the travoprost group was 61.9 (10.6) years; 60.6% were female; and 47.1% were white. The mean (SD) age of the latanoprost group was 60.5 (12.4) years; 62.6% were female; and 49.0% were white. Mean IOP values were not significantly different between the travoprost and latanoprost groups at baseline (24.7 vs 24.2 mm Hg) or 6 weeks; however, the between-group difference in reductions from baseline in pooled IOP during the masked phase of the study was statistically significant (-8.3 vs -7.5 mm Hg; P = 0.009). At weeks 6 and 12, mean lOP levels were 16.1 and 16.2 mm Hg, respectively, in the travoprost group and 16.4 and 16.1 mm Hg in the group that was switched from latanoprost to travoprost (all, P = NS). The most common ocular AEs that occurred with masked travoprost, latanoprost, and open-label travoprost were hyperemia (26.9%, 12.2%, and 5.3%, respectively), discomfort (3.2%, 3.4%, and 1.1%), and pruritus (4.5%, 2.0%, and 2.1%).

Conclusions: In this population of patients with OAG or OH, 6-week treatment with travoprost 0.004% was associated with a significantly greater decrease from baseline in pooled IOP compared with latanoprost 0.005% 20 hours after administration. There were no significant differences between the 2 groups. Travoprost and latanoprost were well tolerated.

References (29)

  • A Heijl et al.

    Reduction of intraocular pressure and glaucoma progression: Results From the Early Manifest Glaucoma Trial

    Arch Ophthalmol

    (2002)
  • RE Marquis et al.

    Management of glaucoma: Focus on pharmacological therapy

    Drugs Aging

    (2005)
  • N Ishida et al.

    Prostanoids in the therapy of glaucoma

    Cardiovasc Drug Rev

    (2006)
  • BJ Gaskin et al.

    Glaucoma management trends in Australia and New Zealand

    Clin Experiment Ophthalmol

    (2006)
  • Cited by (15)

    • Evaluation of investigator bias in industry-funded clinical trials of latanoprost

      2011, Canadian Journal of Ophthalmology
      Citation Excerpt :

      Because of the low number of eligible data sets for bimatoprost and travoprost, statistical analysis was performed only for the latanoprost IOP data sets (47 IOP data sets from 38 articles) (Table 1). The 33 IOP data sets from 29 articles (4 studies were cross-over designs and contributed 2 IOP data sets each) investigating latanoprost provided 1-month data,4,6,8,9,12-36 and 14 data sets from 13 articles (1 study was a cross-over design and contributed 2 data sets) provided 3-month data.7-10,15,18,37-43 Details of the latanoprost studies are provided in Table 2.

    • Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences

      2008, Survey of Ophthalmology
      Citation Excerpt :

      A final aspect to consider when reviewing studies is the difference between statistical and clinical significance, a distinction acknowledged by Konstas et al.79 For IOP-lowering therapy, the FDA considers clinical relevance to be a between-treatment difference greater than 1.5 mm Hg. Using mean diurnal IOP at the final visit as the primary endpoint, all but one of the studies summarized in Table 2 demonstrated a between-treatment difference of less than 1.5 mm Hg.1,30,33,34,36,43,46,47,53,55,57,68,78–80,90,93,95,96,99,102,103,145,158 The exception was the study by Parmaksiz et al102 that found a difference of 1.7 mm Hg in favor of latanoprost over travoprost.

    • Medical treatment: First-line agents, monotherapy, and combination therapy

      2016, Pearls of Glaucoma Management: Second Edition
    View all citing articles on Scopus
    View full text